LIM-kinase 2 (LIMK2) belongs to the LIMK family of proteins, which comprises LIMK1 and LIMK2. Both proteins regulate actin polymerization through phosphorylation and inactivation of the actin depolymerizing factor cofilin. In this study, we show that the level of LIMK2 protein is increased in neuroblastoma, BE(2)-C cells, selected for resistance to microtubule-destabilizing agents, vincristine and colchicine. However, the level of phosphorylated LIMK1 and LIMK2 was similar in the resistant and parental BE(2)-C cells. In contrast, the level of phospho-cofilin was greatly increased in the drugresistant cells. Downregulation of LIMK2 expression increases sensitivity of neuroblastoma SH-EP cells to vincristine and vinblastine but not to microtubule-stabilizing agents, while it's overexpression increased its resistance to vincristine. Its vincristine-induced mitotic arrest was moderately inhibited in the LIMK2 knockdown cells, suggesting that the increased drug sensitivity is through an alternative mechanism other then mitotic arrest and apoptosis. Moreover, downregulation of LIMK2 expression induces formation of abnormal mitotic spindles, an effect enhanced in the presence of microtubule-destabilizing agents. LIMK2 is important for normal mitotic spindle formation and altered LIMK2 expression mediates sensitivity to microtubule destabilizing agents. These findings suggest that inhibition of LIMK2 activity may be used for the treatment of tumors resistant to microtubuledestabilizing drugs.
Introduction
Dynamic interactions between cytoskeletal networks involving microtubules, actin filaments (F-actin) and intermediate filaments are essential for many cellular functions including cell division and cell motility. Microtubules form the mitotic spindle, which is critical for the accurate segregation of chromosomes during mitosis. Microtubule-targeted drugs such as the taxanes and vinca alkaloids disrupt microtubule dynamics and induce mitotic arrest, and subsequent cell death. These anti-mitotic agents are used in the treatment of many malignancies, however, resistance can be a major clinical problem. To date several mechanisms of resistance to anti-mitotic agents have been identified including alterations in the tubulin/microtubule system, the cellular target of microtubule-targeted drugs (reviewed in Verrills and Kavallaris, 2005) . We have recently reported that alterations in the expression of g-actin and actin-associated proteins are associated with resistance to microtubule-targeted drugs (Verrills et al., 2003 (Verrills et al., , 2006a . A microarray study found that expression of LIM-kinase 2 (LIMK2), a regulator of actin dynamics, is a predictive marker of drug resistance (Dan et al., 2002) . However, the functional role of LIMK2 in mediating response to microtubule-targeted drugs has not yet been analysed. LIMK1 and LIMK2 share 50% overall homology. They belong to the LIM kinase family of serine/ threonine proteins and their structure consists of two LIM domains, a PDZ and a kinase domain at the C-terminus (Mizuno et al., 1994; Nunoue et al., 1995; Okano et al., 1995) . The LIMK proteins regulate actin polymerization and reorganization through phosphorylation and inactivation of the actin depolymerizing factor cofilin at Ser-3 thereby inhibiting cofilin from binding to and depolymerizing F-actin (Arber et al., 1998; Yang et al., 1998; Sumi et al., 1999) . The LIMK proteins are activated by phosphorylation at Thr508 (LIMK1) and Thr505 (LIMK2) by ROCK, PAK1 and 4, downstream effectors of the Rho-GTPases: Rho, Rac and Cdc42 (Arber et al., 1998; Yang et al., 1998; Edwards et al., 1999; Sumi et al., 1999 Sumi et al., , 2001 Amano et al., 2001; Dan et al., 2001) . There is increasing evidence that LIMK2 may have an important role in cell cycle progression. Knockdown of LIMK2 expression in NIH3T3 mouse fibroblasts caused an increase in cyclin D1 levels and in addition, the increased level of cyclin A was specific to LIMK2 activation by ROCK but not LIMK1 activation (Croft and Olson, 2006) . The distribution pattern of LIMK2 during cell cycle progression is distinct from LIMK1. LIMK2 is expressed as punctae in the cytoplasm of interphase cells (Acevedo et al., 2006) , and then accumulates in the centrosomes during prometaphase, then localizes to the mitotic spindle during metaphase and early anaphase and to the spindle midzone at late anaphase and telophase (Sumi et al., 2006) . In contrast, LIMK1 is localized in the spindle poles during prometaphase to anaphase and then redistributed to the cleavage furrow in telophase (Sumi et al., 2006) . Sumi et al. suggested that LIMK2 might have a different role in mitotic spindle organization compared with LIMK1. The role of LIMK2 in cell cycle progression is potentially through regulation of microtubule and actin stability.
In this study, we analysed the role of LIMK2 in mediating microtubule-targeted drug response in neuroblastoma cells. The expression of LIMK2 and the phosphorylation of its substrate, cofilin, are greatly increased in neuroblastoma cells selected for resistance to microtubule-destabilizing drugs. Furthermore, silencing of LIMK2 expression by small interfering RNA (siRNA) significantly enhances the sensitivity of neuroblastoma cells to the microtubule-destabilizing drugs, whereas overexpression of LIMK2 in the neuroblastoma SH-EP cells decreased their sensitivity to these drugs. In addition, knockdown of LIMK2 expression induces abnormal mitotic spindles and this effect is enhanced in the presence of vincristine and vinblastine.
Results
Expression of LIMK2, phosphorylated cofilin and phosphorylated LIMK in neuroblastoma cells resistant to microtubule-destabilizing drugs To analyse whether LIMK2 expression levels are associated with resistance to microtubule-targeted drugs, we examined the level of LIMK2 protein in neuroblastoma BE(2)-C cells, vincristine-resistant cells, BE/VCR10, and the colchicine-resistant cells, BE/ CHCb0.2. LIMK2 protein expression was significantly upregulated in the vincristine-resistant BE/CHCb0.2 cells by 1.8-fold (Po0.05) compared with the parental BE(2)-C cells, whereas a trend toward increased expression was observed in the BE/VCR10 (1.6-fold, P ¼ 0.104) ( Figure 1a ).
To address whether the increased LIMK2 level in the drug-resistant cells correlates with an increase in its activity, we examined the level of p-cofilin in the drugresistant cells. To date, the only known LIMK2 substrate is cofilin, an actin depolymerizing protein. Figure 1 Expression of LIM-kinase 2 (LIMK2), phospho-LIMK and phospho-cofilin in neuroblastoma drug-resistant cells. Western blots were probed with anti-LIMK2, anti-p-LIMK (p-LIMK 1/2), anti-p-cofilin, anti-cofilin and anti-GAPDH Abs. (a) Representative immunoblot of BE(2)-C, BE/VCR10 and BE/CHCb0.2 cell lysates probed with anti-LIMK2 mAb and anti-GAPDH Abs as a loading control. The graphs show the ratio between the amounts of LIMK2 protein and GAPDH (loading control) determined by densitometry. The columns represent the mean of triplicate runs; bars, s.e.m. (b) Representative immunoblot of neuroblastoma drugresistant cell lysates probed with anti-p-cofilin, anti-cofilin and anti-GAPDH Abs. The graph shows the ratio between p-cofilin and cofilin and represents the mean of duplicate experiments performed at least twice; bars, s.e.m. (c) Western blot analysis of p-LIMK1 and p-LIMK2. Whole cell lysates of BE(2)-C, BE/VCR10 and BE/CHC0.2b were subjected to immunoprecipitation with anti-LIMK1 or anti-LIMK2 and bound proteins were separated on 4-20% gradient sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), transferred onto nitrocellulose membrane and probed with anti-p-LIMK1/2. Arrows indicate protein bands corresponding to p-LIMK1 and p-LIMK2. The numbers below represent the ratio of p-LIMK1/LIMK1 and p-LIMK2/LIMK2. *Po0.05, On its activation, LIMK2 binds to and phosphorylates cofilin at Ser3. Therefore, increased levels of p-cofilin directly correlate with increased LIMK2 activity. Although the parental BE(2)-C cells expressed low, but detectable levels, of p-cofilin (Ser3) (Figure 1b) , a significant increase in p-cofilin level was observed in both BE/VCR10 (27.9-fold, Po0.01) and BE/CHb0.2 (7.5-fold, Po0.05) cells compared with the parental BE(2)-C cells (Figure 1b) , suggesting increased LIMK2 activity. In contrast, the level of unphosphorylated cofilin was not altered in the parental BE(2)-C cells and the drug-resistant sublines ( Figure 1b) .
As the levels of LIMK2 and the phosphorylation of its substrate cofilin were greatly increased in the resistant cell lines, we also expected increased levels of phosphorylated LIMK2. As the anti-p-LIMK1/2 polyclonal antibodies detect both p-LIMK1 (Thr-508) and p-LIMK2 (Thr-505), we performed immunoprecipitation with either anti-LIMK1 or anti-LIMK2 mAbs followed by immunoblotting with anti-p-LIMK1/2 Abs ( Figure 1c) . No significant changes were observed in the levels of p-LIMK1 or p-LIMK2 between the drug sensitive BE(2)-C and the drug resistant cell lines. Interestingly, the level of p-LIMK2 was significantly higher than that of p-LIMK1 in all the cell lines. These results are surprising as increased levels of LIMK2 and p-cofilin in the resistant cell lines indicate LIMK2 activation. It is therefore possible that LIMK2 is activated by phosphorylation on another residue than Thr-505 (see Discussion).
Knockdown of LIM-kinase 2 expression in neuroblastoma cells affects actin stress fiber formation We have shown that LIMK2 expression is increased in neuroblastoma cells resistant to microtubule-destabilizing drugs, suggesting an association of this protein kinase with drug resistance. To elucidate the role of LIMK2 in mediating drug response, siRNA was used to knockdown LIMK2 expression. As the BE(2)-C cells and the drug-resistant sublines express high levels of the multidrug transporter, P-glycoprotein (LaQuaglia et al., 1991) , siRNA transfection and drug-treated clonogenic assays were performed using neuroblastoma SH-EP cells that have barely detectable levels of P-glycoprotein. LIMK2 protein expression was reduced by approximately 75% in the LIMK2 siRNA-transfected SH-EP cells (mean expression 0.482 ± 0.012, Po0.01) 72 h after transfection compared with the control siRNA transfectants (mean expression 1.927±0.077) (Figure 2a) . Knockdown of LIMK2 expression by siRNA had no effect on LIMK1 expression (data not shown). As LIMK2 is known to regulate the actin cytoskeleton through phosphorylation and inactivation of cofilin, we examined the effects of LIMK2 knockdown on the structure of F-actin. There was no significant difference in the level of b-or g-actin in the LIMK2 knockdown cells compared with the control siRNA transfectants (Figure 2b ). However, staining of the cells with phalloidin, revealed dense staining of the F-actin in the control siRNA transfectants (Figure 2c ), whereas a loss of the F-actin network was observed in the LIMK2 siRNA cells (Figure 2c ), suggesting increased F-actin depolymerization through activation of cofilin. Furthermore, a significant decrease of 36% (Po0.05) in p-cofilin level was observed in the LIMK2 knockdown cells compared with the control (Figure 2d ). These findings suggest that the decrease in actin stress fibers in the LIMK2 knockdown cells is due to decreased p-cofilin levels.
LIM-kinase 2 knockdown increases sensitivity to vinca alkaloids To determine the role of LIMK2 in mediating microtubule-targeted drug sensitivity, drug-treated clonogenic assays were performed. Knockdown of LIMK2 expression significantly increased the sensitivity of the SH-EP cells to vincristine (1.62-fold at the ID 50 , Po0.05) compared with the control siRNA transfectants ( Figure 3a , Table 1 ). Similarly, silencing of LIMK2 significantly sensitized the SH-EP cells to vinblastine by 1.81-fold (Po0.05) at ID 50 , compared with control siRNA-treated cells (Table 1) . In contrast, knockdown of LIMK2 did not significantly alter the sensitivity of the cells to microtubule-stabilizing agents, paclitaxel (Table 1) or epothilone B ( Figure 3b , Table 1 ) compared with the control siRNA-treated cells (Table 1) .
The LIMK2 siRNA-transfected cells accumulated radiolabelled vincristine to a similar extent as the control siRNA transfectants (data not shown), excluding the possibility that increased sensitivity to vinca alkaloids is due to increased uptake of the drugs in the LIMK2 knockdown cells.
To analyse whether the increased sensitivity to vincristine and vinblastine observed in the LIMK2 knockdown cells correlates with enhanced apoptosis the siRNA-transfected SH-EP cells were treated with 0.75, 3 and 10 nM vincristine for 48 h, followed by western blotting for cleaved PARP, a downstream target of caspase-3. Apoptosis was enhanced two-fold in the LIMK2 siRNA-transfected cells treated with low concentrations of vincristine (0.75 nM) but not at higher concentrations of the drug (3 and 10 nM), as shown by cleaved PARP levels compared with the control siRNA ( Supplementary Figure 1) . Similarly, BE(2)-C . The LIMK2 knockdown and control siRNA-transfected cells were seeded into six-well plates and treated with increasing concentrations of vincristine (VCR) and epothilone B (EpoB) for 3 days before incubation in drug-free media for further 5-6 days when colonies were formed. The colonies were visualized by staining with 0.5% crystal violet and counted. Surviving fraction represents colony number/(number of cells seeded Â plating efficiency), (plating efficiency ¼ colony number/number of cells seeded). Each point represents the mean of at least four independent experiments; bars, s.e.m. *Po0.05, statistically significant compared with the control siRNA at each drug concentration. Figure 2A ) followed by vincristine treatment had a dosedependent increase in the number of floating round cells consistent with increased drug sensitivity (Supplementary Figure 2B ). However, this finding was not reflected in enhanced PARP cleavage after LIMK2 knockdown in BE(2)-C cells treated with vincristine (data not shown). Collectively, these data suggest that LIMK2 may be mediating sensitivity to these agents through cell death mechanisms other than apoptosis (see Discussion).
Overexpression of LIMK2 protects SH-EP cells from vinca alkaloid-induced cell death
To confirm the role of LIMK2 in conferring resistance to microtubule-destabilizing drugs, we generated SH-EP cells overexpressing LIMK2 and studied its effect on apoptosis by measuring the level of cleaved PARP. After confirming the expression of the LIMK2 transgene (Supplementary Figure 3A) , we treated the cells with vincristine. Decreased levels of cleaved PARP were observed in SH-EP cells overexpressing LIMK2 in comparison with untransfected cells (Supplementary Figure 3B) , indicating that LIMK2 expression confers resistance to vincristine-induced cell death.
Effect of LIM-kinase 2 knockdown on vincristine-induced mitotic arrest and abnormal mitotic spindles Vinca alkaloids such as vincristine exert their effects by suppressing microtubule dynamics and inducing a potent mitotic block at the G2/M phase of the cell cycle and cell death. To determine whether the increased sensitivity observed in the LIMK2 siRNA-transfected cells is due to the enhanced effect of LIMK2 knockdown on vincristine-and vinblastine-induced mitotic arrest, the siRNA-transfected cells were treated with increasing concentrations of vincristine (0.75-10 nM) and vinblastine (0.1-10 nM) for 22 h to induce mitotic arrest. Knockdown of LIMK2 expression caused a small but significant decrease in mitotic index compared with the control siRNA cells (Figure 4a) . A vincristine-induced dose-dependent increase in mitotic index was observed in the control siRNA transfectants (Figure 4b ). In contrast, a moderate inhibition of vincristine-induced mitotic arrest was observed in the LIMK2 knockdown cells (Figure 4b ). In the presence of 10 nM vincristine, a 2.59-fold increase in mitotic index was observed in the LIMK2 knockdown cells. In contrast, an 8.30-fold increase in mitotic index was observed in the control siRNA-transfected cells (Figure 4b ). Similar results were observed when the siRNA-transfected cells were treated with increasing concentrations of vinblastine (0.1-10 nM) Role of LIMK2 in mitotic stability and drug response ST Po'uha et al (Supplementary Figure 4A) , indicating that LIMK2 may be required for an effective vinca alkaloid-induced mitotic block. Consistent with the mitotic index results, knockdown of LIMK2 reduces the ability of vincristine and vinblastine to induce G2/M cell cycle arrest (data not shown).
We observed that the LIMK2 knockdown cells were proliferating at a slower rate compared with the control siRNA-transfected cells and to determine whether the inhibition of vinca alkaloid-induced mitotic arrest was time dependent, the LIMK2 knockdown and control siRNA-transfected cells were treated for 22-70 h with 10 nM vincristine, a concentration that induced significant mitotic arrest in the control siRNA cells (Figure 4a ). The LIMK2 knockdown cells showed a lower mitotic index after 22-h treatment and had maximal mitotic arrest (16.44±1.99%) after 50-h treatment with 10 nM vincristine (Figure 4c ). In contrast, the control siRNA transfectants had maximal mitotic arrest at 22 h after drug treatment, which then decreased with increasing incubation time (Figure 4c ). Knockdown of LIMK2 appears to significantly reduce the ability of vincristine to induce a mitotic block in the SH-EP cells possibly through a defect in mitotic checkpoints.
We analysed whether the inability of the drugs to induce mitotic arrest was due to a defect in the mitotic checkpoints, enabling the cells to proceed through to anaphase in the presence of vinca alkaloids without arresting in metaphase. Loss of LIMK2 expression neither delayed nor enhanced the onset of anaphase in the SH-EP cells. The anaphase/metaphase ratio and the number of mitotic cells that were in prometaphase/ metaphase and anaphase/telophase phases were similar amongst the LIMK2 and control siRNA cells (Figure 4d, Supplementary Figures 5A and B and Supplementary Table 1 ). These data indicate that onset of anaphase is not delayed in the LIMK2 knockdown cells. Interestingly, knockdown of LIMK2 expression significantly decreased the anaphase/metaphase ratio (ratio 0.150 ± 0.016, Po0.01) in the presence of a low concentration of vincristine (0.75 nM) compared with the control siRNA-treated cells (ratio 0.290±0.019) (Figure 4d ). Furthermore, in the LIMK2 knockdown cells treated with 0.75 nM vincristine, 86.3% of the mitotic cells were in the prometaphase/metaphase stage, whereas 13.7% were in the anaphase/telophase stage compared with 72.1 and 27.9%, respectively, in the control siRNA transfectants (Supplementary Figures 5A  and B and Supplementary Table 1 ). These data show that a majority of the mitotic cells in the LIMK2 siRNA transfectants are in metaphase. In both siRNA transfectants, the anaphase/metaphase ratio decreases with increasing concentrations of vincristine (Figure 4d ) indicating that most of the mitotic cells are arresting in metaphase, thus delaying anaphase onset (Supplementary Figures 5A and B) . Although there was an increase in the number of cells arrested in metaphase relative to the total number of mitotic cells counted, whereas there was no overall increase in mitotic index of the LIMK2 knockdown cells when treated with vinca alkaloids.
Mitotic spindle integrity is crucial for the mitotic progression from metaphase to anaphase and a defect in this spindle assembly checkpoint will result in a delay in anaphase onset. Knockdown of LIMK2 alone induced a significant increase in the formation of abnormal mitotic spindles (4.74-fold; 4.69 ± 0.90%, Po0.05) compared with the control siRNA (0.99 ± 0.41%) (Figure 5a ). The abnormal spindles observed in the LIMK2 siRNA transfectants include metaphase spindles with uncongressed chromosomes and multi-polar spindles (Supplementary Figure 6 ). The formation of abnormal mitotic spindles in the LIMK2 knockdown cells was significantly enhanced in the presence of 0.75 nM vincristine (2.18-fold) compared with the control siRNA-transfected cells (Figure 5b) . Similar results were observed in LIMK2 siRNA cells treated with 0.1 nM vinblastine (Supplementary Figure 4B) . This increase in the percentage of abnormal mitotic spindles correlates with the increase in the percentage of cells arresting in the prometaphase/metaphase stage in the LIMK2 knockdown cells. Again, these data indicate that the onset of anaphase is delayed because of the formation of abnormal spindles, causing arrest in metaphase Table 1 ). The abnormal spindles observed in low concentrations of vincristine include multi-polar spindles with uncongressed chromosomes (Figure 6iv ), ballshaped spindles (Figure 6v ) and bi-polar spindles with uncongressed chromosomes (data not shown) and these types of drug-induced abnormal spindles have been described earlier (Jordan et al., 1991) . The percentage of abnormal mitotic spindles in both the LIMK2 and control siRNA transfectants increases with increasing concentrations of both vincristine (Figures 5b) and vinblastine (Supplementary Figure 4B) . This increase in abnormal mitotic spindles correlates with increased blockage in metaphase and a complete delay in anaphase onset (Supplementary Figures 5A and B and Supplementary Table 1 ). Collectively, these findings indicate that decreased LIMK2 expression induces abnormal mitotic spindles and this effect is increased in the presence of low concentrations of vinca alkaloids. However, this increase in cells arresting in metaphase because of the formation of abnormal mitotic spindles in the LIMK2 knockdown cells does not result in increased mitotic index, but does correlate with increased drug sensitivity.
Discussion
The data presented here show that increased LIMK2 expression and cofilin phosphorylation are associated with resistance to microtubule-destabilizing drugs in neuroblastoma cells. Importantly, knockdown of LIMK2 expression resulted in increased sensitivity of neuroblastoma SH-EP cells to vinca alkaloids, showing for the first time a functional role for LIMK2 in microtubule-destabilizing drug response. This increase in drug sensitivity is potentially mediated by LIMK2- induced formation of abnormal mitotic spindles, an effect enhanced in the presence of vinca alkaloids.
In the neuroblastoma cells resistant to microtubuledestabilizing drugs, the levels of LIMK2 protein and that of p-cofilin were increased while that of p-LIMK2 remained unchanged. The finding that the LIMK2/ cofilin pathway is altered, suggests a potential role for this pathway in regulating microtubule integrity and mediating microtubule-destabilizing drug action. Surprisingly, there was no direct correlation between the levels of p-cofilin and that of p-LIMK2 in the neuroblastoma drug-resistant cells. It was anticipated that the increased LIMK2 and p-cofilin levels observed in the drug-resistant cells would be the result of LIMK2 activation by phosphorylation of Thr-505. However, the level of p-LIMK2 remained unchanged in these cells. The increase in p-cofilin levels in the drug-resistant cells suggests that phosphorylation and inactivation of cofilin may be involved in mediating resistance to microtubuledestabilizing drugs. Furthermore, cofilin alternates between its non-phosphorylated and phosphorylated forms to regulate reorganization of the F-actin (reviewed (Sarmiere and Bamburg, 2004) ). Dephosphorylation of cofilin, restores its actin depolymerizing activity and is regulated by phosphatases such as slingshot (Niwa et al., 2002; Soosairajah et al., 2005) , chronophin (Gohla et al., 2005) and protein phosphatase 1 and 2A (Ambach et al., 2000) . Therefore, it is possible that the level or activity of these cofilin phosphatases is reduced in the neuroblastoma drugresistant cell lines resulting in increased levels of pcofilin. The parental BE(2)-C and the BE/VCR10 cells express similar levels of p-LIMK1 and p-LIMK2, however, in the BE/VCR10 cells p-cofilin levels are higher than in the BE(2C)-C parental cells suggesting that regulation of cofilin phosphorylation and dephosphorylation is altered in the drug-resistant cells. Interestingly, it was recently shown that protein kinase D phosphorylates slingshot and inhibits its activity. It is possible that protein kinase D levels and activity are increased in the drug-resistant cells leading to inhibition of slingshot phosphatase and increased levels of p-cofilin (Eiseler et al., 2009; Peterburs et al., 2009) . Two reports showed that LIMK1 could be activated by phosphorylation on sites other than Thr-508 (Kobayashi et al., 2006) . Similarly, LIMK2 may also be activated by phosphorylation on other sites than Thr-505 resulting in increased cofilin phosphorylation. Hyperphosphorylation of LIMK2 and increased cofilin phosphorylation were observed only in nocodazole synchronized mitotic HeLa cells but not during normal cell cycle progression, suggesting that LIMK2 is activated in response to microtubule disruption taking place during mitosis (Sumi et al., 2006) . Our study shows that cofilin is hyperphosphorylated in the neuroblastoma BE(2)-Cresistant cells with no concomitant LIMK2 phosphorylation on Thr-505. Regardless of the mechanism by which LIMK2 is activated, this is the first demonstration that increased LIMK2 and p-cofilin levels are associated with resistance to microtubule-destabilizing drugs.
Knockdown of LIMK2 enhanced the sensitivity of SH-EP cells specifically to microtubule-destabilizing drugs providing the first functional evidence that LIMK2 mediates response of neuroblastoma cells to microtubule-destabilizing drugs. The mechanism(s) of how LIMK2 regulates microtubule-targeted drug action is not yet known. Earlier studies have shown that LIMK1 regulates microtubule stability (Gorovoy et al., 2005) through phosphorylation of p25 also known as tubulin polymerization promoting protein (Acevedo et al., 2007) . Phosphorylation of p25 by LIMK1 inhibits its ability to polymerize tubulin resulting in microtubule disassembly. However, it is not yet known whether LIMK2 can also regulate microtubule stability through phosphorylation of p25.
Our finding that abnormal mitotic spindle formation is induced by downregulation of LIMK2 expression provides the first functional demonstration that LIMK2 may be important in mitotic spindle formation. The molecular mechanism(s) of how LIMK2 regulates mitosis and its knockdown induces mitotic spindle abnormalities still remains to be determined. Sumi et al. (2006) , suggested that LIMK2 and LIMK1 are required for spindle organization and chromosome segregation and recent studies have confirmed the role of cofilin phosphorylation by LIMK1 in this process (Davila et al., 2007; Kaji et al., 2008) . LIMK2 is localized to the mitotic spindle during metaphase and early anaphase and then redistributed to the spindle midzone and co-localized with midzone microtubules during anaphase and telophase in HeLa cells (Sumi et al., 2006) . The effect of LIMK2 on mitotic spindles may be through regulation of microtubule and actin reorganization during mitosis. During telophase, LIMK2 fails to co-localize with actin or cofilin in the cleavage furrow instead it localizes at the midzone with microtubules (Sumi et al., 2006) . Activation of LIMK2 after microtubule disruption, suggests that LIMK2 function may be required for the mitotic spindle checkpoint when abnormal spindles are formed (Sumi et al., 2006) . Phosphorylated LIMK (p-LIMK1/2), but not its unphosphorylated form, was found to co-localize with g-tubulin at the centrosomes during the early mitotic phases and then accumulates at the cleavage furrow during late telophase . The functional relevance of the different localization of unphosphorylated and phosphorylated LIMK during mitotic progression is not known. However, our data show that loss of LIMK2 perturbs mitotic spindle formation and causes abnormal cell division, suggesting that LIMK2 is required for regulation of microtubule dynamics, which is essential to maintain mitotic spindle assembly.
Microtubule-targeted drug-induced formation of abnormal mitotic spindles correlates with blockage in metaphase and a delay in anaphase onset. LIMK2 knockdown induces abnormal mitotic spindles and consequently the cells are arrested in metaphase, thus restricting progression to anaphase in the presence of low concentrations of vinca alkaloids. Complete inhibition of anaphase onset usually correlates with mitotic arrest, which was observed in the control siRNA cells when treated with either vincristine or vinblastine. On the contrary, vincristine and vinblastine failed to induce a significant increase in mitotic index, regardless of the increased number of cells arresting in metaphase and complete inhibition of anaphase onset in the LIMK2 siRNA cells. Future studies will examine whether loss of LIMK2 function causes defects in several of the cell cycle checkpoints.
Microtubule-targeted drugs induce mitotic arrest and cell death through apoptosis (Bhalla, 2003) . However, mitotic arrest and apoptosis may not be the only mechanism mediating hypersensitivity of LIMK2 knockdown cells to vinca alkaloids. Although we could not show that vincristine-induced apoptosis was enhanced in the LIMK2 knockdown cells compared with the control siRNA transfectants, we showed that the number of round dead floating cells greatly increased in the BE(2)-C LIMK2 siRNA-treated cells. This raises the possibility that the cells may be dying through alternative mechanisms such as mitotic catastrophe or anoikis (Deschesnes et al., 2007) or autophagy (Groth-Pedersen et al., 2007) . As knockdown of LIMK2 enhances vinca alkaloid-induced formation of abnormal mitotic spindles, this may have triggered the onset of mitotic catastrophe, potentially explaining the low levels of vinca alkaloid-induced mitotic block observed in LIMK2 knockdown cells. Importantly, overexpression of LIMK2 in SH-EP cells rendered them resistant to apoptosis induced by vincristine indicating that LIMK2 has an important role in controlling response to these drugs in neuroblastoma cells.
In summary, this study shows that increased LIMK2 expression is associated with resistance to microtubuledestabilizing drugs in childhood neuroblastoma cells. In addition, it provides functional evidence that LIMK2 mediates sensitivity to microtubule-destabilizing drugs. Moreover, this is the first functional study showing that LIMK2 is required for mitotic spindle function. Therefore, LIMK2 can be a potential therapeutic drug target to improve drug sensitivity in childhood neuroblastoma and possibly other cancers treated with microtubuledestabilizing drugs.
Materials and methods

Cell culture
Neuroblastoma cell lines, BE(2)-C and the drug-resistant sublines BE/VCR10 (selected in 10 mg/ml vincristine), BE/ CHC0.2 (selected in 0.2 mg/ml colchicine) (LaQuaglia et al., 1991) and SH-EP were maintained as described earlier (Don et al., 2004) . All cell lines used were free from mycoplasma contamination.
Short interfering RNA gene knockdown SH-EP cells were plated into 24-well plates (1.5 Â 10 4 cells per well) and transfected with LIMK2 (5 0 -AATCGCCTCCGGAA TGGCCTA-3 0 , (Qiagen, Valencia, CA, USA)), control siRNA targeting the GFP (5 0 -CGGCAAGCTGACCCTGAAGT TCAT-3 0 , Qiagen) or All Stars negative control (Qiagen) as described earlier (Verrills et al., 2006b ). LIMK2 siRNA optimization was determined using final concentrations of 20-150 nM followed by western blot analysis at 24-72 h post-siRNA transfection. Optimal knockdown of LIMK2 protein that caused minimal stress to the cells was 100 nM (72 h). The GFP siRNA was used as a negative control siRNA in western blotting and clonogenic assays and the All Stars negative control siRNA was used in the mitosis and apoptosis experiments.
Immunoprecipitation
Neuroblastoma cell lines, BE(2)-C and the drug-resistant sublines BE/VCR10, and BE/CHC0.2b were harvested on ice, using cold lysis buffer (50 mM Tris, pH7.5, 150 mM NaCl, 1% Triton X-100 (Sigma-Aldrich, St Louis, MO, USA), protease inhibitor cocktail (Roche Diagnostics, Indianapolis, IN, USA), phosphatase inhibitor cocktail (Sigma-Aldrich)). Immunoprecipitation was performed as described earlier (Acevedo et al., 2006) . Briefly, whole cell lysates were precleared with protein-G sepharose beads coupled with 2 mg anti-rat IgG2a to remove non-specific binding proteins. Pooled anti-LIMK1, LIMK2 or negative control IgG (3 mg) bound to protein-G sepharose were incubated with precleared whole cell lysates at 4 1C overnight. Beads were washed with modified lysis buffer (0.1% Triton X-100), and boiled in loading buffer to elute bound proteins. Eluted proteins were separated on 4-20% sodium dodecyl sulfate-polyacrylamide gel electrophoresis and transferred onto nitrocellulose membrane for immunoblotting.
Western blot analysis
Total cellular proteins from BE(2)-C drug-resistant cells and siRNA-transfected cells were prepared using standard techniques (Verrills et al., 2006a, b) . Equal amounts of protein (15-50 mg) were resolved on 12% sodium dodecyl sulfatepolyacrylamide gel electrophoresis or 4-20% pre-cast Criterion Tris-HCl gel (Bio-Rad, Hercules, CA, USA) before electrotransfer. Immunoblotting was performed using anti-LIMK2 mAb (Acevedo et al., 2006) , anti-GAPDH (Abcam, Cambridge, UK), anti-b-actin (Sigma-Aldrich), anti-p-LIMK1 (Thr508)/ LIMK2 (Thr505) (Cell Signaling, Beverly, MA, USA), anti-pcofilin (phospho-Ser3), anti-cofilin (Abcam, Cambridge, UK) and anti-g-actin (a gift from P Gunning, University of New South Wales, Australia). The membranes were incubated with HRP-conjugated IgG secondary antibodies and proteins detected with ECL Plus (GE Healthcare Life Sciences, Uppsala, Sweden). The blots were scanned and densitometric analysis performed as described earlier (Verrills et al., 2006b) .
Clonogenic assays SH-EP cells transfected with siRNA were incubated for 72 h, and 150 cells seeded into a six-well plate. Cells were collected for western blotting to confirm LIMK2 knockdown. Clonogenic assays were performed as described earlier with minor modifications (Verrills et al., 2006b) . Cytotoxic drugs were stored and prepared as described earlier (Verrills et al., 2006b) . Briefly, cells were treated with increasing concentrations of vincristine (0.09375-1.5 nM, Sigma-Aldrich), vinblastine (0.025-0.4 nM, David Bull Laboratories, Melbourne, Australia), paclitaxel (0.4-6.4 nM, Merck, Calbiochem, San Diego, CA, USA) and epothilone B (0.025-0.4 nM, Merck, Calbiochem). After 3 days, the media containing the drug was replaced by fresh media and the cells were incubated for a further 5-6 days until colonies were formed. Colonies were counted and expressed as surviving fraction and the ID 50 was calculated as described earlier (Verrills et al., 2006b ).
F-actin staining with phalloidin SH-EP cells were seeded into a four-well glass chamber slide at 1.5 Â 10 4 cells per well (Nalge Nunc International, Naperville, IL, USA) and transfected with siRNA as described above. Staining of the F-actin and imaging were carried out as described earlier (Verrills et al., 2006b) .
Mitotic index and microscopy SH-EP cells were seeded into four-well chamber slides and transfected with siRNA as described above. After 72-h incubation, cells were treated with increasing concentrations of either vincristine (0.75-10 nM) or vinblastine (0.1-10 nM) for 22-h or 10 nM vincristine for 22-70 h. The cells were fixed with formaldehyde (3.7% final concentration), permeabilized with 0.1% Triton X-100 for 1 min and stained with anti-a-tubulin followed with anti-mouse-Alexa Fluor 488 secondary Ab (Molecular Probes-Invitrogen, Carlsbad, CA, USA) to visualize the microtubule network and Vectashield mounting media with 4,6 diamidino-phenylindole (DAPI) (Vector Laboratories Ltd., Burlingame, CA, USA) to visualize chromosomes. Images were captured using an Axiovert 200 M fluorescent microscope (Zeiss, Oberkochen, Germany) 100 Â 1.4 NA Plan lens, coupled to an AxioCamMR3 camera and driven by the Axio Vision software (Zeiss, Oberkochen, Germany). To examine the effect of LIMK2 on vinca alkaloid-induced mitotic arrest, total of at least 1000 interphase and mitotic cells were counted per condition. Quantitative analysis of abnormal mitotic spindle formation was performed by counting on average 500 and 250 mitotic cells for control and LIMK2 siRNA, respectively.
Statistical analysis
Statistical analysis was performed using two-sided, unpaired Student's t-test and values are expressed as mean±s.e.m. Po0.05 was considered statistically significant.
